Abbot Genetics Inc. (AG, https://abbotgenetics.com/) is a U.S.-based early-stage In Vitro Diagnostics Company on the front end of the fight to combat the ravaging effects of the coronavirus. AG technology will be essential in putting people back to work, providing post-pandemic influenza/COVID-19 antibody testing solutions to mitigate future outbreaks, and keeping people working. AG’s COVID-19 Antibody Test Kits are in use worldwide with over 100+ million Point of Care (POC) tests—the most significant usage of any company.
The Harvard Global Health Institute states that the USA needs a minimum of 30 million tests per week (4,300,000 per day) to suppress new infections and keep them low enough to open public life again safely. As of 1 July 2020, current testing in the USA is less than 600,000 tests/day, which is half the number the “mitigation goal” to suppress virus growth.